Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Atopic Dermatitis · Seborrheic Keratosis · ACRS

Aclaris Therapeutics

Aclaris Therapeutics clinical programs — 33 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
170 N Radnor Chester Rd, Radnor Township, Pennsylvania, US HQ
2012 Founded
10 Employees
Public company Type
ACRS · NYSE Ticker
Company details
Status
Public
HQ
170 N Radnor Chester Rd, Radnor Township, Pennsylvania, US
Founded
2012
Employees
10
Programs
33
Drugs
12
Patents
18
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Aclaris Therapeutics projects

33 ClinicalTrials.gov programs sponsored by Aclaris Therapeutics.

Aclaris Therapeutics has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

33 programs

Clinical programs

  1. A-101

    Aclaris Therapeutics

    Common Wart

    phase 3 small molecule completed

    2 trials

  2. A-101 Solution

    Aclaris Therapeutics

    Seborrheic Keratosis

    phase 3 small molecule completed

    3 trials

  3. Active

    Aclaris Therapeutics

    Common Wart

    phase 3 small molecule completed

    1 trial

  4. A-101

    Aclaris Therapeutics

    Seborrheic Keratosis

    phase 2 small molecule completed

    2 trials

  5. A-101 25%

    Aclaris Therapeutics

    Seborrheic Keratosis (SK)

    phase 2 small molecule completed

    1 trial

  6. A-101 Solution 40

    Aclaris Therapeutics

    Common Warts

    phase 2 small molecule completed

    1 trial

  7. A-101 Topical Solution

    Aclaris Therapeutics

    Common Wart

    phase 2 small molecule completed

    2 trials

  8. A-101 Topical Solution 40%

    Aclaris Therapeutics

    Dermatosis Papulosa Nigra

    phase 2 small molecule completed

    1 trial

  9. A-101 Vehicle

    Aclaris Therapeutics

    Seborrheic Keratosis

    phase 2 small molecule completed

    1 trial

  10. ATI 502 0.46% Topical Solution

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  11. ATI-045

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  12. ATI-045, Placebo to ATI-045

    Aclaris Therapeutics

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  13. ATI-1777

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  14. ATI-1777 2.0% w/w

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  15. ATI-2138

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  16. ATI-450

    Aclaris Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  17. ATI-450

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  18. ATI-450

    Aclaris Therapeutics

    Psoriatic Arthritis

    phase 2 small molecule terminated

    1 trial

  19. ATI-450

    Aclaris Therapeutics

    Cryopyrin-Associated Periodic Syndrome

    phase 2 small molecule terminated

    1 trial

  20. ATI-450 50 mg oral tablet BID

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  21. ATI-50002

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule completed

    1 trial

  22. ATI-50002

    Aclaris Therapeutics

    Androgenetic Alopecia

    phase 2 small molecule completed

    1 trial

  23. ATI-50002 high dose

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  24. ATI-50002 topical solution

    Aclaris Therapeutics

    Vitiligo

    phase 2 small molecule completed

    1 trial

  25. ATI-501 400mg BID (Low dose)

    Aclaris Therapeutics

    Alopecia

    phase 2 small molecule completed

    1 trial

  26. ATI-502

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  27. Vehicle

    Aclaris Therapeutics

    Alopecia Universalis (AU)

    phase 2 small molecule completed

    1 trial

  28. Zumsemetinib

    Aclaris Therapeutics

    Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  29. ATI-052-ASTH-101

    Aclaris Therapeutics

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  30. ATI-2231

    Aclaris Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  31. Zunsemetinib

    Aclaris Therapeutics

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

  32. A-101 Topical Solution

    Aclaris Therapeutics

    Seborrheic Keratosis

    approved small molecule completed

    1 trial

  33. Oxymetazoline HCL 1.0% Cream

    Aclaris Therapeutics

    Rosacea

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Aclaris Therapeutics have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.